Ropes & Gray represented Anthos Therapeutics, LLC, a leading investor in Anthos Therapeutics, Inc., in connection with Novartis’ acquisition of Anthos Therapeutics, Inc. for up to $3.1 billion.
Anthos Therapeutics, Inc. was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer.
The Ropes & Gray team representing Anthos Therapeutics, LLC included mergers and acquisitions partner Michael Beauvais, mergers and acquisitions counsel Michael Connolly and venture capital and emerging companies partner Rajarshi Banerjee.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.